UPA UPMAG Semaglutide 5mg – GLP-1 Compound Peptide for Metabolic & Weight Management
Ozempic, also known by its generic name semaglutide, is a medication primarily used for the treatment of type 2 diabetes.
Semaglutide activates the GLP-1 (glucagon-like peptide-1) receptor, producing enhanced insulin secretion in response to meals, suppressed glucagon output, delayed gastric emptying and reduced appetite signals. The agent is increasingly studied for its long-term effects on fat distribution and cardiometabolic outcomes. UPA Labs Semaglutide 5mg has been formulated as a high-potency GLP-1 receptor agonist for advanced research focused on weight reduction, satiety enhancement and metabolic health. Extensive clinical data show its ability to reduce appetite, slow gastric emptying and improve glycaemic control. 
Dosage: 
Week 1 – 0.25mg
Week 2 – 0.5mg
Week 3 – 0.5mg
Week 4 – 0.5mg
Week 5 – Onwards 7.5mg